{"nctId":"NCT02556788","briefTitle":"Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris","startDateStruct":{"date":"2015-11"},"conditions":["Acne Vulgaris"],"count":1212,"armGroups":[{"label":"CD5789 (Trifarotene) 50µg/g Cream","type":"EXPERIMENTAL","interventionNames":["Drug: CD5789 (trifarotene) 50µg/g Cream"]},{"label":"Placebo Cream","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Cream"]}],"interventions":[{"name":"CD5789 (trifarotene) 50µg/g Cream","otherNames":[]},{"name":"Placebo Cream","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The subject is a male or female, 9 years of age or older, at Screening visit.\n* The Subject has moderate acne at Screening and Baseline.\n* The subject is a female of non childbearing potential\n* The subject is a female of childbearing potential with a negative pregnancy test and who is strictly abstinent or who agrees to use an effective and approved contraceptive method for the duration of the study and at least 1 month after the last study drug application.\n\nExclusion Criteria:\n\n* The subject has severe forms of acne (e.g., acne conglobate, acne fulminant) or secondary acne form (e.g.,chloracne, drug-induced acne, etc.).\n* The subject has any uncontrolled or serious disease or any medical or surgical condition that may either interfere with the interpretation of the trial results and/or put the subject at significant risk (according to the Investigator's judgment) if the subject takes part to the trial.\n* The subject has been exposed to excessive ultraviolet (UV) radiation within one month prior to the Baseline visit or the subject is planning intense UV exposure during the study (i.e., occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.)\n* The subject is unwilling to refrain from use of prohibited medication during the clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"9 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)","description":"Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"255","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":602},"commonTop":["Application Site Irritation","Application Site Puritis","Application Site Pain","Application Site Dryness","Sunburn"]}}}